⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
DNLI News
Denali Therapeutics Inc. Common Stock
The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step
prnewswire.com
PRME
IOVA
MDGL
DNLI
Form 8-K
sec.gov
DNLI
Form 8-K
sec.gov
DNLI
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
globenewswire.com
DNLI
Advanced Cell-based Therapy Booming the Success for Healthcare Sector
prnewswire.com
PRME
IOVA
MDGL
DNLI
Form 8-K
sec.gov
DNLI
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
globenewswire.com
DNLI
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
globenewswire.com
WVE
ALNY
DNLI
Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™
globenewswire.com
DNLI
ISPE Announces 2026 Facility of the Year Awards (FOYA) Submission Finalists at the 2026 ISPE Facilities of the Future Conference
prnewswire.com
AZN
DNLI
LLY
JNJ
MRK
MRNA